Search results
Results from the WOW.Com Content Network
Collen Masimirembwa (born 1967) is a biomedical pharmacologist from Zimbabwe.He is a Distinguished Professor of Clinical Pharmacology at the University of Witswatersrand, [1] and serves as the President and Chief Scientific Officer at the African Institute of Biomedical Science and Technology (AiBST).
AstraZeneca's primary listing is on the London Stock Exchange and is a constituent of the FTSE 100 Index; it also has a secondary listing on the Nasdaq Stockholm. It is also listed on the American Nasdaq and is a Nasdaq-100 company. AstraZeneca has one of the highest market capitalisations of pharmaceutical companies worldwide. [12]
The consolidation of AstraZeneca's global R&D footprint will have an impact on sites in the United States. About 1,200 positions will leave Wilmington, while there will be an increase of about 300 ...
Jane Osbourn, OBE, is a scientist and former chair of the UK BioIndustry Association. [1]A Natural Sciences graduate of Queens' College, Cambridge, Osbourn completed several post-graduate qualifications before moving into industry at Cambridge Antibody Technology, that became MedImmune and AstraZeneca.
Golden triangle universities generally do well on international rankings, which strongly reflect research performance. Some global rankings, such as those produced by Times Higher Education (THE) and QS, correct for the sizes of institutions in calculating their results but others, such as the Academic Ranking of World Universities (ARWU), make ...
In August 2012 he was named as the new chief executive of AstraZeneca, [9] the world's fifth largest pharmaceutical company, when aged 53. He took up the post on 1 October 2012. He took up the post on 1 October 2012.
The International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, a 2015 Swiss NGO of pharmaceutical companies and others, defined a contract research organization (CRO), specifically pertaining to clinical trials services as: [8]: 10 "A person or an organization (commercial, academic, or other) contracted by the sponsor to perform one or ...
The doctoral training programme entitled International PhD Programme in Molecular Medicine was launched in October 2005, and, in 2006, established as central facility of Ulm University as “Graduate School in Molecular Medicine”. [11] [12] From 2007 until 2019, IGradU was supported by the DFG (German Research Foundation). [13]